$165 Million is the total value of Stonepine Capital Management, LLC's 25 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -20,374 | -100.0% | -0.15% | – |
| EYEN | Exit | EYENOVIA INC | $0 | – | -39,902 | -100.0% | -0.20% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -380,083 | -100.0% | -0.27% | – |
| IMDZ | Exit | IMMUNE DESIGN CORP | $0 | – | -161,226 | -100.0% | -0.28% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -59,229 | -100.0% | -0.29% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -129,756 | -100.0% | -0.36% | – |
| ZSAN | Exit | ZOSANO PHARMA CORP | $0 | – | -200,000 | -100.0% | -0.54% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -219,022 | -100.0% | -0.55% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -570,987 | -100.0% | -0.63% | – |
| IVTY | Exit | INVUITY INC | $0 | – | -507,028 | -100.0% | -1.05% | – |
| STDY | Exit | STEADYMED LTD | $0 | – | -721,308 | -100.0% | -1.26% | – |
| Exit | MEDICREA INTERNATIONAL | $0 | – | -714,729 | -100.0% | -1.49% | – | |
| OXFD | Exit | OXFORD IMMUNOTEC GLOBAL PLC | $0 | – | -263,974 | -100.0% | -1.76% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -773,889 | -100.0% | -2.31% | – |
| DOVA | Exit | DOVA PHARMACEUTICALS INC | $0 | – | -184,000 | -100.0% | -2.67% | – |
| CRME | Exit | CARDIOME PHARMA CORP | $0 | – | -3,241,550 | -100.0% | -4.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.